Markers and Mechanisms of Vascular Disease in Type II Diabetes

CompletedOBSERVATIONAL
Enrollment

298

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

May 31, 2008

Study Completion Date

May 31, 2008

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Rosiglitazone

ROSIGLITAZONE (roe si GLI ta zone) helps to treat type 2 diabetes. It helps to control blood sugar. Treatment is combined with diet and exercise.

Trial Locations (17)

15240

VA Pittsburgh Health Care System, Pittsburgh

24153

VA Medical Center, Salem VA, Salem

33125

Miami VA Healthcare System, Miami, FL, Miami

40502

VA Medical Center, Lexington, Lexington

55417

VA Medical Center, Minneapolis, Minneapolis

77030

Michael E. DeBakey VA Medical Center (152), Houston

78229

VA South Texas Health Care System, San Antonio, San Antonio

85012

Carl T. Hayden VA Medical Center, Phoenix

85723

Southern Arizona VA Health Care System, Tucson, Tucson

90822

VA Medical Center, Long Beach, Long Beach

92161

VA San Diego Healthcare System, San Diego, San Diego

93703

VA Central California Health Care System, Fresno, Fresno

60141-5000

Edward Hines, Jr. VA Hospital, Hines

46202-2884

Richard Roudebush VA Medical Center, Indianapolis, Indianapolis

68105-1873

VA Medical Center, Omaha, Omaha

07018

VA New Jersey Health Care System, East Orange, East Orange

00921

VA Medical Center, San Juan, San Juan

All Listed Sponsors
collaborator

American Diabetes Association

OTHER

lead

US Department of Veterans Affairs

FED

NCT00256646 - Markers and Mechanisms of Vascular Disease in Type II Diabetes | Biotech Hunter | Biotech Hunter